HUTCHMED Reassesses Gastric Cancer Drug Pathway
Company Announcements

HUTCHMED Reassesses Gastric Cancer Drug Pathway

HUTCHMED (China) Limited (HK:0013) has released an update.

HUTCHMED (China) Limited has withdrawn its supplemental New Drug Application in China for fruquintinib, aimed at treating second-line advanced gastric cancer, following additional internal reviews and discussions with Chinese health authorities that highlighted the current data may not suffice for approval. Despite showing statistically significant improvements in progression-free survival, the data did not demonstrate a statistically significant improvement in overall survival as per the Phase III FRUTIGA trial. The company remains committed to evaluating future possibilities for fruquintinib’s use in gastric cancer treatment, as well as continuing its development for other cancers, including metastatic colorectal cancer.

For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyHutchmed announces new, updated data from sovleplenib ESLIM-01 trial
TipRanks HongKong Auto-Generated NewsdeskHUTCHMED to Present Promising Clinical Data in 2024
TheFlyHutchmed to receive $20M milestone payment from Takeda for Fruzaqla sales
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App